Immune Checkpoint Inhibitors Plus Neoadjuvant Chemotherapy in Early Triple-negative Breast Cancer: A Systematic Review and Meta-analysis

BMC Cancer

PD-1/PD-L1 inhibitors combined with chemotherapy can improve pCR rates and EFS, and with an increased incidence of some immune-related AEs compared with chemotherapy alone. NACT plus ICIs might be an option in patients within PD-L1 positive and high-risk populations with positive nodal disease early TNBC.